SCHEMBL2534052

SCHEMBL2534052

N#Cc1cc(C(=O)Nc2cncnc2Cl)ccc1Cl

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VNN1 O95497 1/20 0.54
GRM4 Q14833 1/20 0.44
KCNQ3 O43525 3/20 0.44
KCNQ2 O43526 3/20 0.44
KCNE1 P15382 3/20 0.44
KCNQ1 P51787 3/20 0.44
RORC P51449 2/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
HTT P42858 1/20 0.41
S1PR3 Q99500 5/20 0.41
S1PR1 P21453 4/20 0.41
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
S1PR4 O95977 2/20 0.39
AKT1 P31749 1/20 0.39
S1PR2 O95136 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4152465 0.89 VNN1 (0.53) VNN1GRM4KCNQ3KCNQ2KCNE1
SCHEMBL14542864 0.77 KCNQ3 (0.65) VNN1GRM4KCNQ3KCNQ2KCNE1
SCHEMBL23458490 0.74 KCNMA1 (0.52) NPC1RAB9AHTTALDH1A1LMNA
SCHEMBL1923606 0.74 PDE4D (0.42) VNN1GRM4KCNQ3KCNQ2KCNE1
SCHEMBL13812239 0.72 LMNA (0.41) VNN1KCNQ3KCNQ2KCNE1KCNQ1
SCHEMBL28253118 0.71 S1PR3 (0.46) VNN1GRM4HTTS1PR3S1PR1
SCHEMBL20185806 0.70 VNN1 (1.00) VNN1
SCHEMBL15867032 0.69 VNN1 (0.56) VNN1GRM4S1PR3MAPT
SCHEMBL6869441 0.68 S1PR3 (0.52) S1PR3S1PR1LMNAS1PR4S1PR2
SCHEMBL8129368 0.68 MAPK3 (0.44) VNN1GRM4S1PR3S1PR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3219319-A1 AGENT FOR OVERCOMING RESISTANCE TO ANTI-CANCER AGENT Nippon Chemiphar Co., Ltd. (JP) 2017-09-20 EP disclosed
EP-2036561-B1 AGENT FOR OVERCOMING RESISTANCE TO ANTI-CANCER AGENT NIPPON CHEMIPHAR CO (JP) 2017-05-10 EP disclosed
US-8314085-B2 Agent for overcoming resistance to anti-cancer agent NIPPON CHEMIPHAR CO., LTD. (JP) 2012-11-20 US disclosed
US-20110257201-A1 AGENT FOR OVERCOMING RESISTANCE TO ANTI-CANCER AGENT NIPPON CHEMIPHAR CO., LTD. (JP) 2011-10-20 US disclosed
US-20100234399-A1 AGENT FOR OVERCOMING RESISTANCE TO ANTI-CANCER AGENT NIPPON CHEMIPHAR CO., LTD. (JP) 2010-09-16 US disclosed
US-20090149452-A1 XANTHINE OXIDASE INHIBITOR NIPPON CHEMIPHAR CO., LTD. (JP) 2009-06-11 US disclosed
US-20090149452-A1 XANTHINE OXIDASE INHIBITOR NIPPON CHEMIPHAR CO., LTD. (JP) 2009-06-11 US disclosed
EP-2036561-A1 AGENT FOR OVERCOMING RESISTANCE TO ANTI-CANCER AGENT Nippon Chemiphar Co., Ltd. (JP) 2009-03-18 EP disclosed
EP-1911760-A1 XANTHINE OXIDASE INHIBITOR Nippon Chemiphar Co., Ltd. (JP) 2008-04-16 EP disclosed
EP-1911760-A1 XANTHINE OXIDASE INHIBITOR Nippon Chemiphar Co., Ltd. (JP) 2008-04-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149452-A1 XANTHINE OXIDASE INHIBITOR XDH, PNPO, CBR1 VNN1 1757/4885GRM4 4605/4885KCNQ3 2704/4885
US-20100234399-A1 AGENT FOR OVERCOMING RESISTANCE TO ANTI-CANCER AGENT TMX1, TPX2, XDH VNN1 1213/4885GRM4 2360/4885KCNQ3 1783/4885
US-20110257201-A1 AGENT FOR OVERCOMING RESISTANCE TO ANTI-CANCER AGENT TMX1, TPX2, XDH VNN1 1213/4885GRM4 2360/4885KCNQ3 1783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.